Antiplatelet Therapy

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood flow to the heart in patie...

April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-valvular atrial fibrillation, the addition of three...

Heparin More Effective Than Bivalirudin in Treating Patients During PCI

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention (PCI) after a heart attack,...

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet thera...

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve....
June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke,...
Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which...
April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for...
Zontivity (vorapaxar) tablets reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood
Atherotech Diagnostics Lab offers warfarin sensitivity, Plavix sensitivity and thrombophilia risk tests. The warfarin and Plavix...
The U.S. Food and Drug Administration approved Kcentra (prothrombin complex concentrate, human) for the urgent reversal of vitamin K...

Articles

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke,...
April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (...
In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in...
acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy
Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the...

Video Center

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost...
1 week 5 days ago
There were several new cardiovascular ultrasound technology advances highlighted at the American...
2 weeks 5 days ago
The key cardiology news coming out of the 2014 meeting for the Society of Nuclear Medicine and...
4 weeks 4 days ago
CVIS, cardiovascular information system, webinar
Join Ascendian Healthcare Consulting and GE Healthcare during a webinar Wednesday, July 16 to learn about the access, productivity, and revenue cycle efficiency benefits of a modern cardiovascular...
The webinar "Implementing Robotic PCI — Why and How to Start a Successful Program" defines optimal strategies for launching a successful robotic percutaneous coronary intervention (PCI) program. The...
This webinar focuses on implementation of different strategies to help clinicians reduce radiation exposure during interventional cardiology procedures, both for patient and operators. It offers an...

Comparison Charts

Sorry there is no data available